Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 28, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the differences in gut bacteria between people with two types of arthritis—spondyloarthritis and rheumatoid arthritis—and healthy individuals. Researchers want to find out if there are specific patterns or changes in the gut bacteria of patients with these conditions. By comparing the gut bacteria of patients to those of healthy volunteers, the study aims to identify unique markers that could help understand these diseases better.

To participate, you need to be at least 18 years old and either diagnosed with spondyloarthritis or rheumatoid arthritis, or be a healthy adult without any chronic illnesses. Participants will have to sign a consent form agreeing to join the study. If you decide to take part, you can expect to provide a sample for testing, and your information will help researchers learn more about how gut bacteria might affect these types of arthritis. It's important to note that certain individuals, like pregnant women or those who have recently taken antibiotics, may not be eligible to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients:
• • Patient ⩾ 18 years;
• • Diagnosed as spondyloarthritis (SpA) according ASAS classification, or rheumatoid polyarthritis according ACR/EULAR;
• • Affiliated to a social security scheme;
• • Have signed the written informed consent form.
• Healthy control subjects:
• • Adult women and men;
• • Subjet free of chronic pathology;
• • Affiliated to a social security scheme;
• • Have signed the written informed consent form.
• Exclusion Criteria:
• Patients:
• • Patients unable to understand the proposed study and/or sign a informed consent form;
• • Pregnant women or breast feeding women;
• • Patient ⩾ 18 years;
• • Patients under guardianship or curatorship;
• • Have taken antibiotic 1 month prior to inclusion or digestive coloscopy 6 months prior inclusion;
• • Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome;
• • Foreign patients under french AME scheme;
• • Patients had have participated in the prior study Microbiart.
• Healthy control subjects:
• • Subjects unable to understand the proposed study and/or sign a informed consent form;
• • Pregnant women or breast feeding women;
• • Subjects \< 18 years;
• • Subjects under guardianship or curatorship;
• • Presenting acute or chronic severe pathology may likely to interfere with the interpret of outcome;
• • Refusal of subjects to participate to the study;
• • Foreign patients under french AME scheme;
• • Subjects had have participated in the prior study Microbiart.